tbuckley/cabot-search huggingface dataset:
Image Gallery: Verrucous porokeratosis with characteristic histopathological and dermoscopic features
Authors: Y. Luo, J. Liu
Journal: British Journal of Dermatology (2017)

Funding sources: Supported by the Milstein Medical Asian American Partnership Foundation Research Project Award in Skin Disease. Conflicts of interest: none declared. Dear Editor, A 35‐year‐old man with verrucous porokeratosis, also known as porokeratosis ptychotropica, presented with well‐demarcated, scaly, red–brown and verrucous plaques on his buttocks and lower extremities for 8 years (a). Histopathological examination (haematoxylin–eosin) revealed a digitate epidermis with columns of parakeratosis in the form of prominent cornoid lamellae, a diminished granular layer and a number of dyskeratotic keratinocytes (b). Dermoscopy of lesions revealed a papillomatous‐like pattern, dotted and globular vessels, a brown band with white rims inside and outside of the band in the periphery, rosette sign and a central scar‐like area (c, d). The patient was treated with acitretin 30 mg per day for 2 months. The skin lesions showed significant improvement. Verrucous porokeratosis can mimic psoriasis and is easily misdiagnosed clinically. Histopathological and dermoscopic examinations help to make a definitive diagnosis.1 2
Association of Central Nervous System Depression With Topical Brimonidine When Used for Hemostasis
Authors: Devorah R. Shagalov, Drew Taylor, Rachel Schleichert, Jonathan Weiss, Eduardo Weiss
Journal: JAMA Dermatology (2017)

Minor bleeding is the most common complication of dermatologic surgery. Topical brimonidine, 0.33%, gel has been reported for the use of hemostasis in dermatologic surgery. The safety profile and risk of systemic toxic effects when brimonidine is used topically for hemostasis is unknown.To determine the risk of systemic toxic effects of topical brimonidine, 0.33%, gel when used for hemostasis.In this case series from a private practice (Hollywood Dermatology), 2 patients presented for dermatologic procedures, complicated by persistent bleeding.Patients were treated with 10 g of brimonidine, 0.33%, gel applied under occlusion for hemostasis.Mental status, cardiopulmonary function.Both patients experienced deterioration of mental status, respiratory depression, and somnolence. Results from cardiac testing, laboratory workup, and imaging were negative for cardiac or neurologic etiology. Both patients improved in less than 24 hours.Topical brimonidine, 0.33%, gel can result in systemic central nervous system toxic effects when used as a hemostatic agent. At present, it is not possible to define a quantity with which brimonidine can be used safely, nor can a safe wound size be defined. We, therefore, urge against the use of topical brimonidine as a hemostatic agent until its safety is further investigated.
Length of mediports use in patients treated with curative intent.
Authors: Aman Opneja, Prashant Gyanendra Tripathi, Melike Oktem, Kenneth David Miller
Journal: Journal of Clinical Oncology (2015)

e17742 Background: Implantable intravenous access devices (ports) are commonly used to safely administer chemotherapy. Previous studies have described complications of ports but there is little information on the duration of port use for patients who are treated with curative intent. Methods: EMR was searched for patients who received port between 2010 - 2012. Cases who received a port for reason other than chemotherapy were excluded. Data including age, sex, duration of chemotherapy, duration of port and complications were recorded. Results: During the years 2010-2012 a total of 240 patients had indwelling ports placed to receive cancer chemotherapy. 156(65%) patients who had advanced cancer were excluded and 21(8%) patients for whom complete data was not available. 63 patients who were receiving adjuvant therapy for earlier stage cancer or curative therapy were selected. The demographics of this group included 26% male and 74% female.Mean age was 60 years. Lymphoma was the most common diagnosis. The median total length of duration of indwelling port was 711 days and median duration from chemotherapy completion to port removal was 307 days.The duration of time after completing treatment that the port remained in place was 0-6 months (32%), 6-12 months(27%), 12-18 months(12.6%), 18-24 months(7%), and > 24 months(20%). Complications of “ports”, most typically occurred during active treatment and included non-functioning/mispositioning 9, infection 1, and local complication 1. Compliance with port maintenance protocol (“flushing”) was 44%. The estimated cost of maintaining the port was $400/visit. Conclusions: Patients who are receiving adjuvant or curative therapy typically receive a defined course of treatment followed by observation. We found that almost 40% of patients still have the port in place for > 1 year and 20% still at two years after completing treatment. The total cost and the possible psychological impact of leaving a port in place for long periods of time needs further study.
TCTAP C-060 Successful Endovascular Aneurysm Repair of an Aortic Occlusion with an Abdominal Aortic Aneurysm
Authors: Naoko Higashino, Osamu Iida, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takuya Tsujimura, Shota Okuno, Masaaki Uematsu
Journal: Journal of the American College of Cardiology (2017)
Erratum: Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction
Authors: Masako Murai, Hiroyuki Yoneyama, Taichi Ezaki, Makoto Suematsu, Yuya Terashima, Akihisa Harada, Hiromasa Hamada, Hitoshi Asakura, Hiromichi Ishikawa, Kouji Matsushima
Journal: Nature Immunology (2003)
Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation
Authors: Juliane Grimm, Marius Bill, Laura Kloss, Madlen Jentzsch, Maria Knyrim, Karoline Schubert, Christine Guenther, Vladan Vucinic, Georg-Nikolaus Franke, Wolfram Poenisch, Michael Cross, Gerhard Behre, Dietger Niederwieser, Sebastian Schwind
Journal: Blood (2015)
The microbiome in respiratory medicine: current challenges and future perspectives
Authors: Rosa Faner, Oriol Sibila, Alvar Agustí, Eric Bernasconi, James D. Chalmers, Gary B. Huffnagle, Chaysavanh Manichanh, Philip L. Molyneaux, Roger Paredes, Vicente Pérez Brocal, Julia Ponomarenko, Sanjay Sethi, Jordi Dorca, Eduard Monsó
Journal: European Respiratory Journal (2017)

The healthy lung has previously been considered to be a sterile organ because standard microbiological culture techniques consistently yield negative results. However, culture-independent techniques report that large numbers of microorganisms coexist in the lung. There are many unknown aspects in the field, but available reports show that the lower respiratory tract microbiota: 1) is similar in healthy subjects to the oropharyngeal microbiota and dominated by members of the Firmicutes, Bacteroidetes and Proteobacteria phyla; 2) shows changes in smokers and well-defined differences in chronic respiratory diseases, although the temporal and spatial kinetics of these changes are only partially known; and 3) shows relatively abundant non-cultivable bacteria in chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis and bronchiectasis, with specific patterns for each disease. In all of these diseases, a loss of diversity, paralleled by an over-representation of Proteobacteria (dysbiosis), has been related to disease severity and exacerbations. However, it is unknown whether dysbiosis is a cause or a consequence of the damage to bronchoalveolar surfaces. Finally, little is known about bacterial functionality and the interactions between viruses, fungi and bacteria. It is expected that future research in bacterial gene expressions, metagenomics longitudinal analysis and host–microbiome animal models will help to move towards targeted microbiome interventions in respiratory diseases.
Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer
Authors: Kelly Y. Kim, Quynh-Thu Le, Sue S. Yom, Benjamin A. Pinsky, Scott V. Bratman, Raymond H. W. Ng, Haja S. El Mubarak, K. C. Allen Chan, Miriam Sander, Barbara A. Conley
Journal: JNCI Journal of the National Cancer Institute (2017)

Clinical studies have shown plasma Epstein-Barr virus (EBV) DNA level to be an independent prognostic biomarker for nasopharyngeal carcinoma (NPC). However, the proportion of NPC patients whose tumors are associated with EBV vary with geographic location, and there are a variety of assays for plasma EBV. To develop the level of evidence needed to demonstrate the clinical utility of plasma EBV DNA detection for NPC patients and encourage widespread adoption of this biomarker test in clinical laboratories, validated harmonized assays are needed. In 2015, the National Cancer Institute (NCI) convened a Workshop on Harmonization of EBV Testing for Nasopharyngeal Cancer, where experts in head and neck oncology and laboratory medicine addressed the limitations of currently available polymerase chain reaction-based EBV DNA quantitation assays and discussed strategies for advancing the development of harmonized EBV DNA assays and their appropriate clinical use. This article presents the key recommendations to direct future efforts in assay harmonization and validation.
Genetic Abnormalities and Prognosis in Pediatric B-Precursor Acute Lymphoblastic Leukemia without Conventional Genetic Abnormalities; Tokyo Children's Cancer Study Group
Authors: Kenro Ohki, Shinsuke Hirabayashi, Akinori Yaguchi, Akinori Yaguchi, Kazuki Terada, Jun Ohkubo, Norio Shiba, Motohiro Kato, Takashi Fukushima, Katsuyoshi Koh, Hayashi Yasuhide, Atsushi Manabe, Akira Ohara, Nobutaka Kiyokawa
Journal: Blood (2016)
Negative Psychosis Prevention Trials
Authors: Denise Lin
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Progress in maternal and child health: how has South Asia fared?
Authors: Nadia Akseer, Mahdis Kamali, Shams E Arifeen, Ashar Malik, Zaid Bhatti, Naveen Thacker, Mahesh Maksey, Harendra D’Silva, Inacio CM da Silva, Zulfiqar A Bhutta
Journal: BMJ (2017)

Although maternal and child health has improved over the past decade, much remains to be done. <b>Nadia Akseer and colleagues</b> highlight the deficiencies and how to ensure progress continues
Recurrent Syncope in the Emergency Department
Authors: Derek S. Chew, Saman Rezazadeh, Robert J. Miller
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
In patients in the emergency department with acute pain, 10, 15, and 30 mg of ketorolac did not differ for pain relief
Authors: Christopher R. Carpenter
Journal: Annals of Internal Medicine (2017)

Source Citation Motov S, Yasavolian M, Likourezos A, et al. Comparison of intravenous ketorolac at three single-dose regimens for treating acute pain in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;Dec 16. [Epub ahead of print.]. 27993418
Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Authors: Zin W. Myint, Gaurav Goel
Journal: Journal of Hematology & Oncology (2017)

Gastrointestinal (GI) cancers are a group of highly aggressive malignancies with a huge disease burden worldwide. There is clearly a significant unmet need for new drugs and therapies to further improve the treatment outcomes of GI malignancies. Immunotherapy is a novel treatment strategy that is emerging as an effective and promising treatment option against several types of cancers. CTLA-4 and PD-1 are critical immune checkpoint molecules that negatively regulate T cell activation via distinct mechanisms. Immune checkpoint blockade with antibodies directed against these pathways has already shown clinical efficacy that has led to their FDA approval in the treatment of several solid tumors including melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and head and neck cancer. This review will summarize the current clinical progress of modern immunotherapy in the field of GI tumors, with a special focus on immune checkpoint blockade.
Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
Authors: Stephanie Sasse, Paul J. Bröckelmann, Helen Goergen, Annette Plütschow, Horst Müller, Stefanie Kreissl, Carolin Buerkle, Sven Borchmann, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert
Journal: Journal of Clinical Oncology (2017)

Purpose Combined-modality treatment is widely considered the standard of care in early-stage Hodgkin lymphoma (HL), and treatment intensity has been reduced over the last years. Long-term follow-up is important to judge both efficacy and safety of the different therapies used. Patients and Methods We analyzed updated follow-up data on 4,276 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorable HL and HD8 and HD11 for early-stage unfavorable HL between 1993 and 2003. Results In HD7 (N = 627; median follow-up, 120 months), combined-modality treatment was superior to extended-field radiotherapy (RT), with 15-year progression-free survival (PFS) of 73% versus 52% (hazard ratio [HR], 0.5; 95% CI, 0.3 to 0.6; P &lt; .001), without differences in overall survival (OS). In HD10 (N = 1,190; median follow-up, 98 months), noninferiority of two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved-field (IF)–RT to more intensive four cycles of ABVD plus 30 Gy IF-RT was confirmed with 10-year PFS of 87% each (HR, 1.0; 95%, 0.6 to 1.5) and OS of 94% each (HR, 0.9; 95% CI, 0.5 to 1.6), respectively. In both trials, no differences in second neoplasias were observed. In HD8 (N = 1,064; median follow-up, 153 months), noninferiority of involved-field RT to extended-field RT regarding PFS was confirmed (HR, 1.0; 95% CI, 0.8 to 1.2). In HD11 (N = 1,395; median follow-up, 106 months), superiority of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at baseline over ABVD was not observed. After BEACOPP baseline , 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.0; 95% CI, 0.7 to 1.5). In contrast, PFS was inferior in ABVD-treated patients receiving 20 Gy instead of 30 Gy IF-RT (10-year PFS, 76% v 84%; HR, 1.5; 95% CI, 1.0 to 2.1). No differences in OS or second neoplasias were observed in in both trials. Conclusion Long-term follow-up data of the four randomized trials largely support the current risk-adapted therapeutic strategies in early-stage HL. Nevertheless, continued follow-up is necessary to assess the long-term safety of currently applied therapeutic strategies.
Range of Risk Factor Levels
Authors: Aidin Rawshani, Araz Rawshani, Stefan Franzén, Björn Eliasson, Ann-Marie Svensson, Mervete Miftaraj, Darren K. McGuire, Naveed Sattar, Annika Rosengren, Soffia Gudbjörnsdottir
Journal: Circulation (2017)

Individuals with type 1 diabetes mellitus (T1DM) have a high risk of cardiovascular complications, but it is unknown to what extent fulfilling all cardiovascular treatment goals is associated with residual risk of mortality and cardiovascular outcomes in those with T1DM compared with the general population.We included all patients ≥18 years of age with T1DM who were registered in the Swedish National Diabetes Register from January 1, 1998, through December 31, 2014, a total of 33 333 patients, each matched for age and sex with 5 controls without diabetes mellitus randomly selected from the population. Patients with T1DM were categorized according to number of risk factors not at target: glycohemoglobin, blood pressure, albuminuria, smoking, and low-density lipoprotein cholesterol. Risk of all-cause mortality, acute myocardial infarction, heart failure hospitalization, and stroke was examined in relation to the number of risk factors at target.The mean follow-up was 10.4 years in the diabetes group. Overall, 2074 of 33 333 patients with diabetes mellitus and 4141 of 166 529 controls died. Risk for all outcomes increased stepwise for each additional risk factor not at target. Adjusted hazard ratios for patients achieving all risk factor targets compared with controls were 1.31 (95% confidence interval [CI], 0.93-1.85) for all-cause mortality, 1.82 (95% CI, 1.15-2.88) for acute myocardial infarction, 1.97 (95% CI, 1.04-3.73) for heart failure hospitalization, and 1.17 (95% CI, 0.51-2.68) for stroke. The hazard ratio for patients versus controls with none of the risk factors meeting target was 7.33 (95% CI, 5.08-10.57) for all-cause mortality, 12.34 (95% CI, 7.91-19.48) for acute myocardial infarction, 15.09 (95% CI, 9.87-23.09) for heart failure hospitalization, and 12.02 (95% CI, 7.66-18.85) for stroke.A steep-graded association exists between decreasing number of cardiovascular risk factors at target and major adverse cardiovascular outcomes among patients with T1DM. However, risks for all outcomes were numerically higher for patients with T1DM compared with controls, even when all risk factors were at target, with risk for acute myocardial infarction and heart failure hospitalization statistically significantly higher.
Incidence and Trends of Infections with Pathogens Transmitted Commonly Through Food and the Effect of Increasing Use of Culture-Independent Diagnostic Tests on Surveillance — Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2013–2016
Authors: Ellyn P. Marder, Paul R. Cieslak, Alicia B. Cronquist, John Dunn, Sarah Lathrop, Therese Rabatsky-Ehr, Patricia Ryan, Kirk Smith, Melissa Tobin-D’Angelo, Duc J. Vugia, Shelley Zansky, Kristin G. Holt, Beverly J. Wolpert, Michael Lynch, Robert Tauxe, Aimee L. Geissler
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Foodborne diseases represent a substantial public health concern in the United States. CDC's Foodborne Diseases Active Surveillance Network (FoodNet) monitors cases reported from 10 U.S. sites* of laboratory-diagnosed infections caused by nine enteric pathogens commonly transmitted through food. This report describes preliminary surveillance data for 2016 on the nine pathogens and changes in incidences compared with 2013-2015. In 2016, FoodNet identified 24,029 infections, 5,512 hospitalizations, and 98 deaths caused by these pathogens. The use of culture-independent diagnostic tests (CIDTs) by clinical laboratories to detect enteric pathogens has been steadily increasing since FoodNet began surveying clinical laboratories in 2010 (1). CIDTs complicate the interpretation of FoodNet surveillance data because pathogen detection could be affected by changes in health care provider behaviors or laboratory testing practices (2). Health care providers might be more likely to order CIDTs because these tests are quicker and easier to use than traditional culture methods, a circumstance that could increase pathogen detection (3). Similarly, pathogen detection could also be increasing as clinical laboratories adopt DNA-based syndromic panels, which include pathogens not often included in routine stool culture (4,5). In addition, CIDTs do not yield isolates, which public health officials rely on to distinguish pathogen subtypes, determine antimicrobial resistance, monitor trends, and detect outbreaks. To obtain isolates for infections identified by CIDTs, laboratories must perform reflex culture†; if clinical laboratories do not, the burden of culturing falls to state public health laboratories, which might not be able to absorb that burden as the adoption of these tests increases (2). Strategies are needed to preserve access to bacterial isolates for further characterization and to determine the effect of changing trends in testing practices on surveillance.
Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction
Authors: Netusha Thevaranjan, Alicja Puchta, Christian Schulz, Avee Naidoo, J.C. Szamosi, Chris P. Verschoor, Dessi Loukov, Louis P. Schenck, Jennifer Jury, Kevin P. Foley, Jonathan D. Schertzer, Maggie J. Larché, Donald J. Davidson, Elena F. Verdú, Michael G. Surette, Dawn M.E. Bowdish
Journal: Cell Host & Microbe (2017)

Levels of inflammatory mediators in circulation are known to increase with age, but the underlying cause of this age-associated inflammation is debated. We find that, when maintained under germ-free conditions, mice do not display an age-related increase in circulating pro-inflammatory cytokine levels. A higher proportion of germ-free mice live to 600 days than their conventional counterparts, and macrophages derived from aged germ-free mice maintain anti-microbial activity. Co-housing germ-free mice with old, but not young, conventionally raised mice increases pro-inflammatory cytokines in the blood. In tumor necrosis factor (TNF)-deficient mice, which are protected from age-associated inflammation, age-related microbiota changes are not observed. Furthermore, age-associated microbiota changes can be reversed by reducing TNF using anti-TNF therapy. These data suggest that aging-associated microbiota promote inflammation and that reversing these age-related microbiota changes represents a potential strategy for reducing age-associated inflammation and the accompanying morbidity.
Erratum: Corrigendum: Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse
Authors: J M Bomar, P J Benke, E L Slattery, R Puttagunta, L P Taylor, E Seong, A Nystuen, W Chen, R L Albin, P D Patel, R A Kittles, V C Sheffield, M Burmeister
Journal: Nature Genetics (2005)